+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Beta Blockers Market by Type, Application, Distribution Channel - Global Forecast 2025-2030- Product Image
Beta Blockers Market by Type, Application, Distribution Channel - Global Forecast 2025-2030- Product Image
Sale

Beta Blockers Market by Type, Application, Distribution Channel - Global Forecast 2025-2030

  • PDF Icon

    Report

  • 195 Pages
  • October 2024
  • Region: Global
  • 360iResearch™
  • ID: 5967704
UP TO OFF until Dec 31st 2024
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Beta Blockers Market grew from USD 10.54 billion in 2023 to USD 11.06 billion in 2024. It is expected to continue growing at a CAGR of 5.23%, reaching USD 15.08 billion by 2030.

Beta blockers, or beta-adrenergic blocking agents, are medications that reduce blood pressure by blocking the effects of the hormone epinephrine. Their scope encompasses treating a range of conditions such as hypertension, angina, heart attack, and arrhythmias. The necessity of beta blockers arises from their effectiveness in managing cardiovascular diseases, which are leading causes of morbidity and mortality globally. They also find application in treating anxiety and glaucoma, showcasing their versatile end-use scope. Market growth is significantly influenced by the rising prevalence of cardiovascular diseases, increasing geriatric population, and growing awareness of preventative healthcare. Additionally, beta blockers' expanding applications in treating migraines and hyperthyroidism further stimulate demand. However, the market faces limitations such as side effects, including fatigue and dizziness, and contraindications in asthmatic patients, which may restrain growth. Another challenge is the availability of alternative treatments with fewer side effects, affecting market preference. Opportunities lie in personalized medicine and developing beta blockers with targeted delivery mechanisms to minimize side effects. Continued research on combination therapies that improve efficacy with enhanced patient compliance could also provide growth avenues. The latest innovations focus on optimizing formulations for specific patient demographics and creating advanced molecules with lesser cardiac-specific adverse effects. Market players should prioritize investing in strategic collaborations for product development and robust clinical trials to validate safety and efficacy, thereby gaining a competitive advantage. Regions with inadequate access to healthcare offer untapped potential for market penetration. Despite challenges, the beta blocker market exhibits robust growth potential driven by ongoing drug development and shifting healthcare priorities towards disease prevention. Adapting to regulatory changes and patient needs will be essential for sustaining competitiveness in this evolving landscape.

Understanding Market Dynamics in the Beta Blockers Market

The Beta Blockers Market is rapidly evolving, shaped by dynamic supply and demand trends. These insights provide companies with actionable intelligence to drive investments, develop strategies, and seize emerging opportunities. A comprehensive understanding of market dynamics also helps organizations mitigate political, geographical, technical, social, and economic risks while offering a clearer view of consumer behavior and its effects on manufacturing costs and purchasing decisions.
  • Market Drivers
    • Rising aging population more susceptible to heart-related conditions
    • Increasing role of beta blockers in managing congestive heart failure, cardiac arrhythmias, and hyperthyroidism
    • Public health initiatives and awareness programs by governments and healthcare organizations
  • Market Restraints
    • Incidence of product recall
  • Market Opportunities
    • Growing research and development (R&D) activities for the development of individualized beta-blocker treatment for high blood pressure
    • Novel trends in analytical methods for beta blockers
  • Market Challenges
    • Side effects associated with the consumption of beta blockers

Exploring Porter’s Five Forces for the Beta Blockers Market

Porter’s Five Forces framework further strengthens the insights of the Beta Blockers Market, delivering a clear and effective methodology for understanding the competitive landscape. This tool enables companies to evaluate their current competitive standing and explore strategic repositioning by assessing businesses’ power dynamics and market positioning. It is also instrumental in determining the profitability of new ventures, helping companies leverage their strengths, address weaknesses, and avoid potential pitfalls.

Applying PESTLE Analysis to the Beta Blockers Market

External macro-environmental factors deeply influence the performance of the Beta Blockers Market, and the PESTLE analysis provides a comprehensive framework for understanding these influences. By examining Political, Economic, Social, Technological, Legal, and Environmental elements, this analysis offers organizations critical insights into potential opportunities and risks. It also helps businesses anticipate changes in regulations, consumer behavior, and economic trends, enabling them to make informed, forward-looking decisions.

Analyzing Market Share in the Beta Blockers Market

The Beta Blockers Market share analysis evaluates vendor performance. This analysis provides a clear view of each vendor’s standing in the competitive landscape by comparing key metrics such as revenue, customer base, and other critical factors. Additionally, it highlights market concentration, fragmentation, and trends in consolidation, empowering vendors to make strategic decisions that enhance their market position.

Evaluating Vendor Success with the FPNV Positioning Matrix in the Beta Blockers Market

The Beta Blockers Market FPNV Positioning Matrix is crucial in evaluating vendors based on business strategy and product satisfaction levels. By segmenting vendors into four quadrants - Forefront (F), Pathfinder (P), Niche (N), and Vital (V) - this matrix helps users make well-informed decisions that best align with their unique needs and objectives in the market.

Strategic Recommendations for Success in the Beta Blockers Market

The Beta Blockers Market strategic analysis is essential for organizations aiming to strengthen their position in the global market. A comprehensive review of resources, capabilities, and performance helps businesses identify opportunities for improvement and growth. This approach empowers companies to navigate challenges in the increasingly competitive landscape, ensuring they capitalize on new opportunities and align with long-term success.

Key Company Profiles

The report delves into recent significant developments in the Beta Blockers Market, highlighting leading vendors and their innovative profiles. These include AdvaCare Pharma, Amneal Pharmaceuticals LLC, ANI Pharmaceuticals, Inc., AstraZeneca PLC, Baxter International Inc., Bayer AG, Boehringer Ingelheim International GmbH, Bristol-Myers Squibb Company, Cipla Limited, DAIICHI SANKYO COMPANY, LIMITED, Dr. Reddy’s Laboratories Ltd., Eagle Pharmaceuticals, Inc., GlaxoSmithKline PLC, Lupin Limited, Merck & Co., Inc., Neuracle Lifesciences Private Limited, Novartis AG, Pfizer Inc., Recordati Industria Chimica e Farmaceutica S.p.A., Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd., The Menarini Group, and Viatris Inc..

Market Segmentation & Coverage

This research report categorizes the Beta Blockers Market to forecast the revenues and analyze trends in each of the following sub-markets:
  • Type
    • Beta Non-selective Blocker
      • Labetalol
      • Penbutolol Sulfate
      • Pindolol
      • Sotalol Hydrochloride
    • Beta-1 Selective Blocker
      • Acebutolol
      • Atenolol
      • Bisoprolol
      • Metoprolol
  • Application
    • Cardiac Diseases
      • Angina
      • Atrial Fibrillation
      • Heart Failure
    • Glaucoma
    • Hypertension
  • Distribution Channel
    • Hospital Pharmacies
    • Retail Pharmacies
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

The report provides a detailed overview of the market, exploring several key areas:

  1. Market Penetration: A thorough examination of the current market landscape, featuring comprehensive data from leading industry players and analyzing their reach and influence across the market.
  2. Market Development: The report identifies significant growth opportunities in emerging markets and assesses expansion potential within established segments, providing a roadmap for future development.
  3. Market Diversification: In-depth coverage of recent product launches, untapped geographic regions, significant industry developments, and strategic investments reshaping the market landscape.
  4. Competitive Assessment & Intelligence: A detailed analysis of the competitive landscape, covering market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, technological advancements, and innovations in manufacturing by key market players.
  5. Product Development & Innovation: Insight into groundbreaking technologies, R&D efforts, and product innovations that will drive the market in future.

Additionally, the report addresses key questions to assist stakeholders in making informed decisions:

  1. What is the current size of the market, and how is it expected to grow?
  2. Which products, segments, and regions present the most attractive investment opportunities?
  3. What are the prevailing technology trends and regulatory factors influencing the market?
  4. How do top vendors rank regarding market share and competitive positioning?
  5. What revenue sources and strategic opportunities guide vendors' market entry or exit decisions?

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Rising aging population more susceptible to heart-related conditions
5.1.1.2. Increasing role of beta blockers in managing congestive heart failure, cardiac arrhythmias, and hyperthyroidism
5.1.1.3. Public health initiatives and awareness programs by governments and healthcare organizations
5.1.2. Restraints
5.1.2.1. Incidence of product recall
5.1.3. Opportunities
5.1.3.1. Growing research and development (R&D) activities for the development of individualized beta-blocker treatment for high blood pressure
5.1.3.2. Novel trends in analytical methods for beta blockers
5.1.4. Challenges
5.1.4.1. Side effects associated with the consumption of beta blockers
5.2. Market Segmentation Analysis
5.2.1. Type: Rising consumption of beta-1 selective blockers to address respiratory concerns
5.2.2. Application: Increasing usage of beta blockers as an adrenaline in managing various cardiovascular conditions
5.3. Porter’s Five Forces Analysis
5.3.1. Threat of New Entrants
5.3.2. Threat of Substitutes
5.3.3. Bargaining Power of Customers
5.3.4. Bargaining Power of Suppliers
5.3.5. Industry Rivalry
5.4. PESTLE Analysis
5.4.1. Political
5.4.2. Economic
5.4.3. Social
5.4.4. Technological
5.4.5. Legal
5.4.6. Environmental
6. Beta Blockers Market, by Type
6.1. Introduction
6.2. Beta Non-selective Blocker
6.2.1. Labetalol
6.2.2. Penbutolol Sulfate
6.2.3. Pindolol
6.2.4. Sotalol Hydrochloride
6.3. Beta-1 Selective Blocker
6.3.1. Acebutolol
6.3.2. Atenolol
6.3.3. Bisoprolol
6.3.4. Metoprolol
7. Beta Blockers Market, by Application
7.1. Introduction
7.2. Cardiac Diseases
7.2.1. Angina
7.2.2. Atrial Fibrillation
7.2.3. Heart Failure
7.3. Glaucoma
7.4. Hypertension
8. Beta Blockers Market, by Distribution Channel
8.1. Introduction
8.2. Hospital Pharmacies
8.3. Retail Pharmacies
9. Americas Beta Blockers Market
9.1. Introduction
9.2. Argentina
9.3. Brazil
9.4. Canada
9.5. Mexico
9.6. United States
10. Asia-Pacific Beta Blockers Market
10.1. Introduction
10.2. Australia
10.3. China
10.4. India
10.5. Indonesia
10.6. Japan
10.7. Malaysia
10.8. Philippines
10.9. Singapore
10.10. South Korea
10.11. Taiwan
10.12. Thailand
10.13. Vietnam
11. Europe, Middle East & Africa Beta Blockers Market
11.1. Introduction
11.2. Denmark
11.3. Egypt
11.4. Finland
11.5. France
11.6. Germany
11.7. Israel
11.8. Italy
11.9. Netherlands
11.10. Nigeria
11.11. Norway
11.12. Poland
11.13. Qatar
11.14. Russia
11.15. Saudi Arabia
11.16. South Africa
11.17. Spain
11.18. Sweden
11.19. Switzerland
11.20. Turkey
11.21. United Arab Emirates
11.22. United Kingdom
12. Competitive Landscape
12.1. Market Share Analysis, 2023
12.2. FPNV Positioning Matrix, 2023
12.3. Competitive Scenario Analysis
12.3.1. FDA Approved VELSIPITY, An Advancement To Treat Active Ulcerative Colitis
12.3.2. "New Ultra-Short-Acting Beta Blocker, Landiolol, Received Canadian Approval For Critical Care Cardiac Conditions
12.3.3. Ajanta Pharma Launched Met-XL AMT, A New Dual-Action Tablet for Simplified and Effective Hypertension Management
12.4. Strategy Analysis & Recommendation
List of Figures
FIGURE 1. BETA BLOCKERS MARKET RESEARCH PROCESS
FIGURE 2. BETA BLOCKERS MARKET SIZE, 2023 VS 2030
FIGURE 3. GLOBAL BETA BLOCKERS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 4. GLOBAL BETA BLOCKERS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL BETA BLOCKERS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL BETA BLOCKERS MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
FIGURE 7. GLOBAL BETA BLOCKERS MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 8. GLOBAL BETA BLOCKERS MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
FIGURE 9. GLOBAL BETA BLOCKERS MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 10. GLOBAL BETA BLOCKERS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
FIGURE 11. GLOBAL BETA BLOCKERS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 12. AMERICAS BETA BLOCKERS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 13. AMERICAS BETA BLOCKERS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 14. UNITED STATES BETA BLOCKERS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
FIGURE 15. UNITED STATES BETA BLOCKERS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 16. ASIA-PACIFIC BETA BLOCKERS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 17. ASIA-PACIFIC BETA BLOCKERS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 18. EUROPE, MIDDLE EAST & AFRICA BETA BLOCKERS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 19. EUROPE, MIDDLE EAST & AFRICA BETA BLOCKERS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 20. BETA BLOCKERS MARKET SHARE, BY KEY PLAYER, 2023
FIGURE 21. BETA BLOCKERS MARKET, FPNV POSITIONING MATRIX, 2023
List of Tables
TABLE 1. BETA BLOCKERS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
TABLE 3. GLOBAL BETA BLOCKERS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL BETA BLOCKERS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL BETA BLOCKERS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. BETA BLOCKERS MARKET DYNAMICS
TABLE 7. GLOBAL BETA BLOCKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL BETA BLOCKERS MARKET SIZE, BY BETA NON-SELECTIVE BLOCKER, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL BETA BLOCKERS MARKET SIZE, BY LABETALOL, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL BETA BLOCKERS MARKET SIZE, BY PENBUTOLOL SULFATE, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL BETA BLOCKERS MARKET SIZE, BY PINDOLOL, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL BETA BLOCKERS MARKET SIZE, BY SOTALOL HYDROCHLORIDE, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL BETA BLOCKERS MARKET SIZE, BY BETA NON-SELECTIVE BLOCKER, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL BETA BLOCKERS MARKET SIZE, BY BETA-1 SELECTIVE BLOCKER, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL BETA BLOCKERS MARKET SIZE, BY ACEBUTOLOL, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL BETA BLOCKERS MARKET SIZE, BY ATENOLOL, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL BETA BLOCKERS MARKET SIZE, BY BISOPROLOL, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL BETA BLOCKERS MARKET SIZE, BY METOPROLOL, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL BETA BLOCKERS MARKET SIZE, BY BETA-1 SELECTIVE BLOCKER, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL BETA BLOCKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL BETA BLOCKERS MARKET SIZE, BY CARDIAC DISEASES, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL BETA BLOCKERS MARKET SIZE, BY ANGINA, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL BETA BLOCKERS MARKET SIZE, BY ATRIAL FIBRILLATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL BETA BLOCKERS MARKET SIZE, BY HEART FAILURE, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL BETA BLOCKERS MARKET SIZE, BY CARDIAC DISEASES, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL BETA BLOCKERS MARKET SIZE, BY GLAUCOMA, BY REGION, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL BETA BLOCKERS MARKET SIZE, BY HYPERTENSION, BY REGION, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL BETA BLOCKERS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL BETA BLOCKERS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL BETA BLOCKERS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 31. AMERICAS BETA BLOCKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 32. AMERICAS BETA BLOCKERS MARKET SIZE, BY BETA NON-SELECTIVE BLOCKER, 2018-2030 (USD MILLION)
TABLE 33. AMERICAS BETA BLOCKERS MARKET SIZE, BY BETA-1 SELECTIVE BLOCKER, 2018-2030 (USD MILLION)
TABLE 34. AMERICAS BETA BLOCKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 35. AMERICAS BETA BLOCKERS MARKET SIZE, BY CARDIAC DISEASES, 2018-2030 (USD MILLION)
TABLE 36. AMERICAS BETA BLOCKERS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 37. AMERICAS BETA BLOCKERS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 38. ARGENTINA BETA BLOCKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 39. ARGENTINA BETA BLOCKERS MARKET SIZE, BY BETA NON-SELECTIVE BLOCKER, 2018-2030 (USD MILLION)
TABLE 40. ARGENTINA BETA BLOCKERS MARKET SIZE, BY BETA-1 SELECTIVE BLOCKER, 2018-2030 (USD MILLION)
TABLE 41. ARGENTINA BETA BLOCKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 42. ARGENTINA BETA BLOCKERS MARKET SIZE, BY CARDIAC DISEASES, 2018-2030 (USD MILLION)
TABLE 43. ARGENTINA BETA BLOCKERS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 44. BRAZIL BETA BLOCKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 45. BRAZIL BETA BLOCKERS MARKET SIZE, BY BETA NON-SELECTIVE BLOCKER, 2018-2030 (USD MILLION)
TABLE 46. BRAZIL BETA BLOCKERS MARKET SIZE, BY BETA-1 SELECTIVE BLOCKER, 2018-2030 (USD MILLION)
TABLE 47. BRAZIL BETA BLOCKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 48. BRAZIL BETA BLOCKERS MARKET SIZE, BY CARDIAC DISEASES, 2018-2030 (USD MILLION)
TABLE 49. BRAZIL BETA BLOCKERS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 50. CANADA BETA BLOCKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 51. CANADA BETA BLOCKERS MARKET SIZE, BY BETA NON-SELECTIVE BLOCKER, 2018-2030 (USD MILLION)
TABLE 52. CANADA BETA BLOCKERS MARKET SIZE, BY BETA-1 SELECTIVE BLOCKER, 2018-2030 (USD MILLION)
TABLE 53. CANADA BETA BLOCKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 54. CANADA BETA BLOCKERS MARKET SIZE, BY CARDIAC DISEASES, 2018-2030 (USD MILLION)
TABLE 55. CANADA BETA BLOCKERS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 56. MEXICO BETA BLOCKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 57. MEXICO BETA BLOCKERS MARKET SIZE, BY BETA NON-SELECTIVE BLOCKER, 2018-2030 (USD MILLION)
TABLE 58. MEXICO BETA BLOCKERS MARKET SIZE, BY BETA-1 SELECTIVE BLOCKER, 2018-2030 (USD MILLION)
TABLE 59. MEXICO BETA BLOCKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 60. MEXICO BETA BLOCKERS MARKET SIZE, BY CARDIAC DISEASES, 2018-2030 (USD MILLION)
TABLE 61. MEXICO BETA BLOCKERS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 62. UNITED STATES BETA BLOCKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 63. UNITED STATES BETA BLOCKERS MARKET SIZE, BY BETA NON-SELECTIVE BLOCKER, 2018-2030 (USD MILLION)
TABLE 64. UNITED STATES BETA BLOCKERS MARKET SIZE, BY BETA-1 SELECTIVE BLOCKER, 2018-2030 (USD MILLION)
TABLE 65. UNITED STATES BETA BLOCKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 66. UNITED STATES BETA BLOCKERS MARKET SIZE, BY CARDIAC DISEASES, 2018-2030 (USD MILLION)
TABLE 67. UNITED STATES BETA BLOCKERS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 68. UNITED STATES BETA BLOCKERS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 69. ASIA-PACIFIC BETA BLOCKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 70. ASIA-PACIFIC BETA BLOCKERS MARKET SIZE, BY BETA NON-SELECTIVE BLOCKER, 2018-2030 (USD MILLION)
TABLE 71. ASIA-PACIFIC BETA BLOCKERS MARKET SIZE, BY BETA-1 SELECTIVE BLOCKER, 2018-2030 (USD MILLION)
TABLE 72. ASIA-PACIFIC BETA BLOCKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 73. ASIA-PACIFIC BETA BLOCKERS MARKET SIZE, BY CARDIAC DISEASES, 2018-2030 (USD MILLION)
TABLE 74. ASIA-PACIFIC BETA BLOCKERS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 75. ASIA-PACIFIC BETA BLOCKERS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 76. AUSTRALIA BETA BLOCKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 77. AUSTRALIA BETA BLOCKERS MARKET SIZE, BY BETA NON-SELECTIVE BLOCKER, 2018-2030 (USD MILLION)
TABLE 78. AUSTRALIA BETA BLOCKERS MARKET SIZE, BY BETA-1 SELECTIVE BLOCKER, 2018-2030 (USD MILLION)
TABLE 79. AUSTRALIA BETA BLOCKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 80. AUSTRALIA BETA BLOCKERS MARKET SIZE, BY CARDIAC DISEASES, 2018-2030 (USD MILLION)
TABLE 81. AUSTRALIA BETA BLOCKERS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 82. CHINA BETA BLOCKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 83. CHINA BETA BLOCKERS MARKET SIZE, BY BETA NON-SELECTIVE BLOCKER, 2018-2030 (USD MILLION)
TABLE 84. CHINA BETA BLOCKERS MARKET SIZE, BY BETA-1 SELECTIVE BLOCKER, 2018-2030 (USD MILLION)
TABLE 85. CHINA BETA BLOCKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 86. CHINA BETA BLOCKERS MARKET SIZE, BY CARDIAC DISEASES, 2018-2030 (USD MILLION)
TABLE 87. CHINA BETA BLOCKERS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 88. INDIA BETA BLOCKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 89. INDIA BETA BLOCKERS MARKET SIZE, BY BETA NON-SELECTIVE BLOCKER, 2018-2030 (USD MILLION)
TABLE 90. INDIA BETA BLOCKERS MARKET SIZE, BY BETA-1 SELECTIVE BLOCKER, 2018-2030 (USD MILLION)
TABLE 91. INDIA BETA BLOCKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 92. INDIA BETA BLOCKERS MARKET SIZE, BY CARDIAC DISEASES, 2018-2030 (USD MILLION)
TABLE 93. INDIA BETA BLOCKERS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 94. INDONESIA BETA BLOCKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 95. INDONESIA BETA BLOCKERS MARKET SIZE, BY BETA NON-SELECTIVE BLOCKER, 2018-2030 (USD MILLION)
TABLE 96. INDONESIA BETA BLOCKERS MARKET SIZE, BY BETA-1 SELECTIVE BLOCKER, 2018-2030 (USD MILLION)
TABLE 97. INDONESIA BETA BLOCKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 98. INDONESIA BETA BLOCKERS MARKET SIZE, BY CARDIAC DISEASES, 2018-2030 (USD MILLION)
TABLE 99. INDONESIA BETA BLOCKERS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 100. JAPAN BETA BLOCKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 101. JAPAN BETA BLOCKERS MARKET SIZE, BY BETA NON-SELECTIVE BLOCKER, 2018-2030 (USD MILLION)
TABLE 102. JAPAN BETA BLOCKERS MARKET SIZE, BY BETA-1 SELECTIVE BLOCKER, 2018-2030 (USD MILLION)
TABLE 103. JAPAN BETA BLOCKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 104. JAPAN BETA BLOCKERS MARKET SIZE, BY CARDIAC DISEASES, 2018-2030 (USD MILLION)
TABLE 105. JAPAN BETA BLOCKERS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 106. MALAYSIA BETA BLOCKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 107. MALAYSIA BETA BLOCKERS MARKET SIZE, BY BETA NON-SELECTIVE BLOCKER, 2018-2030 (USD MILLION)
TABLE 108. MALAYSIA BETA BLOCKERS MARKET SIZE, BY BETA-1 SELECTIVE BLOCKER, 2018-2030 (USD MILLION)
TABLE 109. MALAYSIA BETA BLOCKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 110. MALAYSIA BETA BLOCKERS MARKET SIZE, BY CARDIAC DISEASES, 2018-2030 (USD MILLION)
TABLE 111. MALAYSIA BETA BLOCKERS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 112. PHILIPPINES BETA BLOCKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 113. PHILIPPINES BETA BLOCKERS MARKET SIZE, BY BETA NON-SELECTIVE BLOCKER, 2018-2030 (USD MILLION)
TABLE 114. PHILIPPINES BETA BLOCKERS MARKET SIZE, BY BETA-1 SELECTIVE BLOCKER, 2018-2030 (USD MILLION)
TABLE 115. PHILIPPINES BETA BLOCKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 116. PHILIPPINES BETA BLOCKERS MARKET SIZE, BY CARDIAC DISEASES, 2018-2030 (USD MILLION)
TABLE 117. PHILIPPINES BETA BLOCKERS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 118. SINGAPORE BETA BLOCKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 119. SINGAPORE BETA BLOCKERS MARKET SIZE, BY BETA NON-SELECTIVE BLOCKER, 2018-2030 (USD MILLION)
TABLE 120. SINGAPORE BETA BLOCKERS MARKET SIZE, BY BETA-1 SELECTIVE BLOCKER, 2018-2030 (USD MILLION)
TABLE 121. SINGAPORE BETA BLOCKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 122. SINGAPORE BETA BLOCKERS MARKET SIZE, BY CARDIAC DISEASES, 2018-2030 (USD MILLION)
TABLE 123. SINGAPORE BETA BLOCKERS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 124. SOUTH KOREA BETA BLOCKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 125. SOUTH KOREA BETA BLOCKERS MARKET SIZE, BY BETA NON-SELECTIVE BLOCKER, 2018-2030 (USD MILLION)
TABLE 126. SOUTH KOREA BETA BLOCKERS MARKET SIZE, BY BETA-1 SELECTIVE BLOCKER, 2018-2030 (USD MILLION)
TABLE 127. SOUTH KOREA BETA BLOCKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 128. SOUTH KOREA BETA BLOCKERS MARKET SIZE, BY CARDIAC DISEASES, 2018-2030 (USD MILLION)
TABLE 129. SOUTH KOREA BETA BLOCKERS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 130. TAIWAN BETA BLOCKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 131. TAIWAN BETA BLOCKERS MARKET SIZE, BY BETA NON-SELECTIVE BLOCKER, 2018-2030 (USD MILLION)
TABLE 132. TAIWAN BETA BLOCKERS MARKET SIZE, BY BETA-1 SELECTIVE BLOCKER, 2018-2030 (USD MILLION)
TABLE 133. TAIWAN BETA BLOCKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 134. TAIWAN BETA BLOCKERS MARKET SIZE, BY CARDIAC DISEASES, 2018-2030 (USD MILLION)
TABLE 135. TAIWAN BETA BLOCKERS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 136. THAILAND BETA BLOCKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 137. THAILAND BETA BLOCKERS MARKET SIZE, BY BETA NON-SELECTIVE BLOCKER, 2018-2030 (USD MILLION)
TABLE 138. THAILAND BETA BLOCKERS MARKET SIZE, BY BETA-1 SELECTIVE BLOCKER, 2018-2030 (USD MILLION)
TABLE 139. THAILAND BETA BLOCKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 140. THAILAND BETA BLOCKERS MARKET SIZE, BY CARDIAC DISEASES, 2018-2030 (USD MILLION)
TABLE 141. THAILAND BETA BLOCKERS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 142. VIETNAM BETA BLOCKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 143. VIETNAM BETA BLOCKERS MARKET SIZE, BY BETA NON-SELECTIVE BLOCKER, 2018-2030 (USD MILLION)
TABLE 144. VIETNAM BETA BLOCKERS MARKET SIZE, BY BETA-1 SELECTIVE BLOCKER, 2018-2030 (USD MILLION)
TABLE 145. VIETNAM BETA BLOCKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 146. VIETNAM BETA BLOCKERS MARKET SIZE, BY CARDIAC DISEASES, 2018-2030 (USD MILLION)
TABLE 147. VIETNAM BETA BLOCKERS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 148. EUROPE, MIDDLE EAST & AFRICA BETA BLOCKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 149. EUROPE, MIDDLE EAST & AFRICA BETA BLOCKERS MARKET SIZE, BY BETA NON-SELECTIVE BLOCKER, 2018-2030 (USD MILLION)
TABLE 150. EUROPE, MIDDLE EAST & AFRICA BETA BLOCKERS MARKET SIZE, BY BETA-1 SELECTIVE BLOCKER, 2018-2030 (USD MILLION)
TABLE 151. EUROPE, MIDDLE EAST & AFRICA BETA BLOCKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 152. EUROPE, MIDDLE EAST & AFRICA BETA BLOCKERS MARKET SIZE, BY CARDIAC DISEASES, 2018-2030 (USD MILLION)
TABLE 153. EUROPE, MIDDLE EAST & AFRICA BETA BLOCKERS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 154. EUROPE, MIDDLE EAST & AFRICA BETA BLOCKERS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 155. DENMARK BETA BLOCKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 156. DENMARK BETA BLOCKERS MARKET SIZE, BY BETA NON-SELECTIVE BLOCKER, 2018-2030 (USD MILLION)
TABLE 157. DENMARK BETA BLOCKERS MARKET SIZE, BY BETA-1 SELECTIVE BLOCKER, 2018-2030 (USD MILLION)
TABLE 158. DENMARK BETA BLOCKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 159. DENMARK BETA BLOCKERS MARKET SIZE, BY CARDIAC DISEASES, 2018-2030 (USD MILLION)
TABLE 160. DENMARK BETA BLOCKERS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 161. EGYPT BETA BLOCKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 162. EGYPT BETA BLOCKERS MARKET SIZE, BY BETA NON-SELECTIVE BLOCKER, 2018-2030 (USD MILLION)
TABLE 163. EGYPT BETA BLOCKERS MARKET SIZE, BY BETA-1 SELECTIVE BLOCKER, 2018-2030 (USD MILLION)
TABLE 164. EGYPT BETA BLOCKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 165. EGYPT BETA BLOCKERS MARKET SIZE, BY CARDIAC DISEASES, 2018-2030 (USD MILLION)
TABLE 166. EGYPT BETA BLOCKERS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 167. FINLAND BETA BLOCKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 168. FINLAND BETA BLOCKERS MARKET SIZE, BY BETA NON-SELECTIVE BLOCKER, 2018-2030 (USD MILLION)
TABLE 169. FINLAND BETA BLOCKERS MARKET SIZE, BY BETA-1 SELECTIVE BLOCKER, 2018-2030 (USD MILLION)
TABLE 170. FINLAND BETA BLOCKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 171. FINLAND BETA BLOCKERS MARKET SIZE, BY CARDIAC DISEASES, 2018-2030 (USD MILLION)
TABLE 172. FINLAND BETA BLOCKERS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 173. FRANCE BETA BLOCKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 174. FRANCE BETA BLOCKERS MARKET SIZE, BY BETA NON-SELECTIVE BLOCKER, 2018-2030 (USD MILLION)
TABLE 175. FRANCE BETA BLOCKERS MARKET SIZE, BY BETA-1 SELECTIVE BLOCKER, 2018-2030 (USD MILLION)
TABLE 176. FRANCE BETA BLOCKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 177. FRANCE BETA BLOCKERS MARKET SIZE, BY CARDIAC DISEASES, 2018-2030 (USD MILLION)
TABLE 178. FRANCE BETA BLOCKERS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 179. GERMANY BETA BLOCKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 180. GERMANY BETA BLOCKERS MARKET SIZE, BY BETA NON-SELECTIVE BLOCKER, 2018-2030 (USD MILLION)
TABLE 181. GERMANY BETA BLOCKERS MARKET SIZE, BY BETA-1 SELECTIVE BLOCKER, 2018-2030 (USD MILLION)
TABLE 182. GERMANY BETA BLOCKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 183. GERMANY BETA BLOCKERS MARKET SIZE, BY CARDIAC DISEASES, 2018-2030 (USD MILLION)
TABLE 184. GERMANY BETA BLOCKERS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 185. ISRAEL BETA BLOCKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 186. ISRAEL BETA BLOCKERS MARKET SIZE, BY BETA NON-SELECTIVE BLOCKER, 2018-2030 (USD MILLION)
TABLE 187. ISRAEL BETA BLOCKERS MARKET SIZE, BY BETA-1 SELECTIVE BLOCKER, 2018-2030 (USD MILLION)
TABLE 188. ISRAEL BETA BLOCKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 189. ISRAEL BETA BLOCKERS MARKET SIZE, BY CARDIAC DISEASES, 2018-2030 (USD MILLION)
TABLE 190. ISRAEL BETA BLOCKERS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 191. ITALY BETA BLOCKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 192. ITALY BETA BLOCKERS MARKET SIZE, BY BETA NON-SELECTIVE BLOCKER, 2018-2030 (USD MILLION)
TABLE 193. ITALY BETA BLOCKERS MARKET SIZE, BY BETA-1 SELECTIVE BLOCKER, 2018-2030 (USD MILLION)
TABLE 194. ITALY BETA BLOCKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 195. ITALY BETA BLOCKERS MARKET SIZE, BY CARDIAC DISEASES, 2018-2030 (USD MILLION)
TABLE 196. ITALY BETA BLOCKERS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 197. NETHERLANDS BETA BLOCKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 198. NETHERLANDS BETA BLOCKERS MARKET SIZE, BY BETA NON-SELECTIVE BLOCKER, 2018-2030 (USD MILLION)
TABLE 199. NETHERLANDS BETA BLOCKERS MARKET SIZE, BY BETA-1 SELECTIVE BLOCKER, 2018-2030 (USD MILLION)
TABLE 200. NETHERLANDS BETA BLOCKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 201. NETHERLANDS BETA BLOCKERS MARKET SIZE, BY CARDIAC DISEASES, 2018-2030 (USD MILLION)
TABLE 202. NETHERLANDS BETA BLOCKERS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 203. NIGERIA BETA BLOCKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 204. NIGERIA BETA BLOCKERS MARKET SIZE, BY BETA NON-SELECTIVE BLOCKER, 2018-2030 (USD MILLION)
TABLE 205. NIGERIA BETA BLOCKERS MARKET SIZE, BY BETA-1 SELECTIVE BLOCKER, 2018-2030 (USD MILLION)
TABLE 206. NIGERIA BETA BLOCKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 207. NIGERIA BETA BLOCKERS MARKET SIZE, BY CARDIAC DISEASES, 2018-2030 (USD MILLION)
TABLE 208. NIGERIA BETA BLOCKERS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 209. NORWAY BETA BLOCKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 210. NORWAY BETA BLOCKERS MARKET SIZE, BY BETA NON-SELECTIVE BLOCKER, 2018-2030 (USD MILLION)
TABLE 211. NORWAY BETA BLOCKERS MARKET SIZE, BY BETA-1 SELECTIVE BLOCKER, 2018-2030 (USD MILLION)
TABLE 212. NORWAY BETA BLOCKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 213. NORWAY BETA BLOCKERS MARKET SIZE, BY CARDIAC DISEASES, 2018-2030 (USD MILLION)
TABLE 214. NORWAY BETA BLOCKERS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 215. POLAND BETA BLOCKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 216. POLAND BETA BLOCKERS MARKET SIZE, BY BETA NON-SELECTIVE BLOCKER, 2018-2030 (USD MILLION)
TABLE 217. POLAND BETA BLOCKERS MARKET SIZE, BY BETA-1 SELECTIVE BLOCKER, 2018-2030 (USD MILLION)
TABLE 218. POLAND BETA BLOCKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 219. POLAND BETA BLOCKERS MARKET SIZE, BY CARDIAC DISEASES, 2018-2030 (USD MILLION)
TABLE 220. POLAND BETA BLOCKERS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 221. QATAR BETA BLOCKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 222. QATAR BETA BLOCKERS MARKET SIZE, BY BETA NON-SELECTIVE BLOCKER, 2018-2030 (USD MILLION)
TABLE 223. QATAR BETA BLOCKERS MARKET SIZE, BY BETA-1 SELECTIVE BLOCKER, 2018-2030 (USD MILLION)
TABLE 224. QATAR BETA BLOCKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 225. QATAR BETA BLOCKERS MARKET SIZE, BY CARDIAC DISEASES, 2018-2030 (USD MILLION)
TABLE 226. QATAR BETA BLOCKERS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 227. RUSSIA BETA BLOCKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 228. RUSSIA BETA BLOCKERS MARKET SIZE, BY BETA NON-SELECTIVE BLOCKER, 2018-2030 (USD MILLION)
TABLE 229. RUSSIA BETA BLOCKERS MARKET SIZE, BY BETA-1 SELECTIVE BLOCKER, 2018-2030 (USD MILLION)
TABLE 230. RUSSIA BETA BLOCKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 231. RUSSIA BETA BLOCKERS MARKET SIZE, BY CARDIAC DISEASES, 2018-2030 (USD MILLION)
TABLE 232. RUSSIA BETA BLOCKERS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 233. SAUDI ARABIA BETA BLOCKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 234. SAUDI ARABIA BETA BLOCKERS MARKET SIZE, BY BETA NON-SELECTIVE BLOCKER, 2018-2030 (USD MILLION)
TABLE 235. SAUDI ARABIA BETA BLOCKERS MARKET SIZE, BY BETA-1 SELECTIVE BLOCKER, 2018-2030 (USD MILLION)
TABLE 236. SAUDI ARABIA BETA BLOCKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 237. SAUDI ARABIA BETA BLOCKERS MARKET SIZE, BY CARDIAC DISEASES, 2018-2030 (USD MILLION)
TABLE 238. SAUDI ARABIA BETA BLOCKERS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 239. SOUTH AFRICA BETA BLOCKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 240. SOUTH AFRICA BETA BLOCKERS MARKET SIZE, BY BETA NON-SELECTIVE BLOCKER, 2018-2030 (USD MILLION)
TABLE 241. SOUTH AFRICA BETA BLOCKERS MARKET SIZE, BY BETA-1 SELECTIVE BLOCKER, 2018-2030 (USD MILLION)
TABLE 242. SOUTH AFRICA BETA BLOCKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 243. SOUTH AFRICA BETA BLOCKERS MARKET SIZE, BY CARDIAC DISEASES, 2018-2030 (USD MILLION)
TABLE 244. SOUTH AFRICA BETA BLOCKERS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 245. SPAIN BETA BLOCKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 246. SPAIN BETA BLOCKERS MARKET SIZE, BY BETA NON-SELECTIVE BLOCKER, 2018-2030 (USD MILLION)
TABLE 247. SPAIN BETA BLOCKERS MARKET SIZE, BY BETA-1 SELECTIVE BLOCKER, 2018-2030 (USD MILLION)
TABLE 248. SPAIN BETA BLOCKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 249. SPAIN BETA BLOCKERS MARKET SIZE, BY CARDIAC DISEASES, 2018-2030 (USD MILLION)
TABLE 250. SPAIN BETA BLOCKERS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 251. SWEDEN BETA BLOCKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 252. SWEDEN BETA BLOCKERS MARKET SIZE, BY BETA NON-SELECTIVE BLOCKER, 2018-2030 (USD MILLION)
TABLE 253. SWEDEN BETA BLOCKERS MARKET SIZE, BY BETA-1 SELECTIVE BLOCKER, 2018-2030 (USD MILLION)
TABLE 254. SWEDEN BETA BLOCKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 255. SWEDEN BETA BLOCKERS MARKET SIZE, BY CARDIAC DISEASES, 2018-2030 (USD MILLION)
TABLE 256. SWEDEN BETA BLOCKERS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 257. SWITZERLAND BETA BLOCKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 258. SWITZERLAND BETA BLOCKERS MARKET SIZE, BY BETA NON-SELECTIVE BLOCKER, 2018-2030 (USD MILLION)
TABLE 259. SWITZERLAND BETA BLOCKERS MARKET SIZE, BY BETA-1 SELECTIVE BLOCKER, 2018-2030 (USD MILLION)
TABLE 260. SWITZERLAND BETA BLOCKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 261. SWITZERLAND BETA BLOCKERS MARKET SIZE, BY CARDIAC DISEASES, 2018-2030 (USD MILLION)
TABLE 262. SWITZERLAND BETA BLOCKERS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 263. TURKEY BETA BLOCKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 264. TURKEY BETA BLOCKERS MARKET SIZE, BY BETA NON-SELECTIVE BLOCKER, 2018-2030 (USD MILLION)
TABLE 265. TURKEY BETA BLOCKERS MARKET SIZE, BY BETA-1 SELECTIVE BLOCKER, 2018-2030 (USD MILLION)
TABLE 266. TURKEY BETA BLOCKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 267. TURKEY BETA BLOCKERS MARKET SIZE, BY CARDIAC DISEASES, 2018-2030 (USD MILLION)
TABLE 268. TURKEY BETA BLOCKERS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 269. UNITED ARAB EMIRATES BETA BLOCKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 270. UNITED ARAB EMIRATES BETA BLOCKERS MARKET SIZE, BY BETA NON-SELECTIVE BLOCKER, 2018-2030 (USD MILLION)
TABLE 271. UNITED ARAB EMIRATES BETA BLOCKERS MARKET SIZE, BY BETA-1 SELECTIVE BLOCKER, 2018-2030 (USD MILLION)
TABLE 272. UNITED ARAB EMIRATES BETA BLOCKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 273. UNITED ARAB EMIRATES BETA BLOCKERS MARKET SIZE, BY CARDIAC DISEASES, 2018-2030 (USD MILLION)
TABLE 274. UNITED ARAB EMIRATES BETA BLOCKERS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 275. UNITED KINGDOM BETA BLOCKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 276. UNITED KINGDOM BETA BLOCKERS MARKET SIZE, BY BETA NON-SELECTIVE BLOCKER, 2018-2030 (USD MILLION)
TABLE 277. UNITED KINGDOM BETA BLOCKERS MARKET SIZE, BY BETA-1 SELECTIVE BLOCKER, 2018-2030 (USD MILLION)
TABLE 278. UNITED KINGDOM BETA BLOCKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 279. UNITED KINGDOM BETA BLOCKERS MARKET SIZE, BY CARDIAC DISEASES, 2018-2030 (USD MILLION)
TABLE 280. UNITED KINGDOM BETA BLOCKERS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 281. BETA BLOCKERS MARKET SHARE, BY KEY PLAYER, 2023
TABLE 282. BETA BLOCKERS MARKET, FPNV POSITIONING MATRIX, 2023

Companies Mentioned

The leading players in the Beta Blockers Market, which are profiled in this report, include:
  • AdvaCare Pharma
  • Amneal Pharmaceuticals LLC
  • ANI Pharmaceuticals, Inc.
  • AstraZeneca PLC
  • Baxter International Inc.
  • Bayer AG
  • Boehringer Ingelheim International GmbH
  • Bristol-Myers Squibb Company
  • Cipla Limited
  • DAIICHI SANKYO COMPANY, LIMITED
  • Dr. Reddy’s Laboratories Ltd.
  • Eagle Pharmaceuticals, Inc.
  • GlaxoSmithKline PLC
  • Lupin Limited
  • Merck & Co., Inc.
  • Neuracle Lifesciences Private Limited
  • Novartis AG
  • Pfizer Inc.
  • Recordati Industria Chimica e Farmaceutica S.p.A.
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • The Menarini Group
  • Viatris Inc.

Methodology

Loading
LOADING...

Table Information

Report AttributeDetails
No. of Pages195
PublishedOctober 2024
Forecast Period2024 - 2030
Estimated Market Value ( USD ) in 2024 $ 11.06 Billion
Forecasted Market Value ( USD ) by 2030 $ 15.08 Billion
Compound Annual Growth Rate5.2%
Regions CoveredGlobal
No. of Companies Mentioned24

Related Topics

Related Reports

Beta Blockers Global Market Report 2024 - Product Image

Beta Blockers Global Market Report 2024

  • Report
  • 200 Pages
  • Global
From
Beta blockers Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2019-2029F - Product Image

Beta blockers Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2019-2029F

  • Report
  • 185 Pages
  • Global
From
Angina Pectoris Drugs Market Size, Share & Trends Analysis Report By Type (Stable Angina, Unstable Angina), By Drug Class (Beta Blockers, Anticoagulants), By Distribution Channel, By Region, And Segment Forecasts, 2024 - 2030 - Product Image

Angina Pectoris Drugs Market Size, Share & Trends Analysis Report By Type (Stable Angina, Unstable Angina), By Drug Class (Beta Blockers, Anticoagulants), By Distribution Channel, By Region, And Segment Forecasts, 2024 - 2030

  • Report
  • 100 Pages
  • Global
From
Antiarrhythmic Drugs Market Size, Share & Trends Analysis Report by Drug Class (Beta Blockers, Sodium Channel Blockers), Route of Administration (Oral, Parenteral), Distribution Channel, Region, and Segment Forecasts, 2024-2030 - Product Image

Antiarrhythmic Drugs Market Size, Share & Trends Analysis Report by Drug Class (Beta Blockers, Sodium Channel Blockers), Route of Administration (Oral, Parenteral), Distribution Channel, Region, and Segment Forecasts, 2024-2030

  • Report
  • 120 Pages
  • Global
From
Beta Receptor Antagonist - Pipeline Insight, 2024 - Product Image

Beta Receptor Antagonist - Pipeline Insight, 2024

  • Clinical Trials
  • 90 Pages
  • Global
From

About the Beta Blocker Market

Beta blockers are a type of cardiovascular drug used to treat a variety of conditions, including hypertension, angina, and arrhythmias. They work by blocking the action of epinephrine, a hormone that can cause the heart to beat faster and with more force. Beta blockers can also reduce the risk of stroke and heart attack by decreasing the workload on the heart. They are also used to treat anxiety and migraines. Beta blockers are generally well-tolerated and have few side effects. Common side effects include fatigue, dizziness, and cold hands and feet. They can also interact with other medications, so it is important to discuss any potential interactions with a doctor before taking them. The beta blocker market is highly competitive, with many companies offering different formulations and dosages. Some of the major players in the market include AstraZeneca, GlaxoSmithKline, Merck, Pfizer, and Novartis. Show Less Read more

Copyright © 2002-2024 Research and Markets. All Rights Reserved.